{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:53:21Z","timestamp":1788537201274,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/Fellowship\/0038\/2016"],"award-info":[{"award-number":["NMRC\/Fellowship\/0038\/2016"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jns.2018.05.020","type":"journal-article","created":{"date-parts":[[2018,5,27]],"date-time":"2018-05-27T09:31:43Z","timestamp":1527413503000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1\/CASPR2 antibodies"],"prefix":"10.1016","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-0953","authenticated-orcid":false,"given":"Tianrong","family":"Yeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok Pin","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Yut Wan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah Yui Huei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2018.05.020_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrneurol.2017.43","article-title":"The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis","volume":"13","author":"van Sonderen","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2018.05.020_bb0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.05.020_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp-2016-314758","article-title":"Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies","volume":"88","author":"Lang","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.05.020_bb0020","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2018.05.020_bb0025","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.05.020_bb0030","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.05.020_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2017.04.045","article-title":"Detection of LGI1 and CASPR2 antibodies with a commercial cell-based assay in patients with very high VGKC-complex antibody levels","volume":"378","author":"Yeo","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2018.05.020_bb0040","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2018.05.020_bb0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.05.020_bb0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jnnp-2014-308695","article-title":"Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease","volume":"86","author":"Rossi","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.05.020_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ana.22674","article-title":"Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol","volume":"71","author":"Meeusen","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.05.020_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.05.020_bb0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/jnnp-2013-305218","article-title":"Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral Centre","volume":"85","author":"Paterson","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.05.020_bb0070","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.05.020_bb0075","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T08:02:20Z","timestamp":1534838540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18302442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":15,"alternative-id":["S0022510X18302442"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.05.020","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1\/CASPR2 antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}